Acta Oncologica is an international peer-reviewed journal based in the Nordic countries. The journal welcomes international contributions and offers global reach.
Acta Oncologica provides the scientific community with a platform for innovative, comprehensive and clinically relevant cancer research. We strive to publish impactful cancer research with potential to influence future oncology and aim to advance high-quality, clinically relevant cancer research across the broad field of oncology.
Acta Oncologica is owned by the non-for-profit Acta Oncologica Foundation and is the official scientific journal for the Nordic National Oncology Societies and the Nordic Association of Clinical Physics (NACP).
Acta Oncologica provides a forum for the exchange of information on the etiology, prevention, diagnosis and treatment of all cancer types.
The journal welcomes articles in the following emerging areas:
Cancer epidemiology
Cancer diagnostics, biomarkers and precision medicine
Medical oncology, radiotherapy and radiophysics
Survivorship, rehabilitation, late side effects and palliative care
Clinical trial protocols (in letter format)
Acta Oncologica publishes original research articles, review articles, letters/brief communications and editorial comments.
Acta Oncologica’s editorial team is committed to efficient, rigorous and constructive peer-review and fair evaluations. The journal operates a single-anonymized peer review policy.
Journal metrics
Usage
1.3M annual downloads/views
Citation metrics
3.1 (2022) Impact Factor
3.9 (2022) 5 year IF
5.8 (2022) CiteScore (Scopus)
Q1 CiteScore Best Quartile
1.127 (2022) SNIP
0.957 (2022) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors
who are deciding where to submit their next manuscript for publication.
However, any one metric only tells a part of the story of a journal’s
quality and impact. Each metric has its limitations which means that it
should never be considered in isolation, and metrics should be used to
support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside
other qualitative factors such as a journal’s aims & scope, its
readership, and a review of past content published in the journal. In
addition, a single article should always be assessed on its own merits and
never based on the metrics of the journal it was published in.
Usage and acceptance rate data above are for the last full calendar year
and are updated annually in February. Speed data is updated every six
months, based on the prior six months. Citation metrics are updated
annually mid-year. Please note that some journals do not display all of
the following metrics
(find out why).
Usage:
the total number of times articles in the journal were viewed by users
of Taylor & Francis Online in the previous calendar year, rounded to the
nearest thousand.
Citation Metrics
Impact Factor*:
the average number of citations received by articles published in the
journal within a two-year window. Only journals in the Clarivate Science
Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI),
Arts and Humanities Citation Index (AHCI) and the Emerging Sources
Citation Index (ESCI) have an Impact Factor.
Impact Factor Best Quartile*:
the journal’s highest subject category ranking in the Journal Citation
Reports. Q1 = 25% of journals with the highest Impact Factors.
5 Year Impact Factor*:
the average number of citations received by articles in the journal
within a five-year window.
CiteScore (Scopus)†:
the average number of citations received by articles in the journal over
a four-year period.
CiteScore Best Quartile†:
the journal’s highest CiteScore ranking in a Scopus subject category. Q1
= 25% of journals with the highest CiteScores.
SNIP
(Source Normalized Impact per Paper):
the number of citations per paper in the journal, divided by citation
potential in the field.
SJR
(Scimago Journal Rank):
Average number of (weighted) citations in one year, divided by the
number of articles published in the journal in the previous three years.
Speed/acceptance
From submission to first decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision. Based on manuscripts receiving a
first decision in the last six months.
From submission to first post-review decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision if it is sent out for peer review.
Based on manuscripts receiving a post-review first decision in the last
six months.
From acceptance to online publication:
the average (median) number of days from acceptance of a manuscript to
online publication of the Version of Record. Based on articles published
in the last six months.
Acceptance rate:
articles accepted for publication by the journal in the previous
calendar year as percentage of all papers receiving a final decision.
Acta Oncologica is indexed/tracked/covered by the following services:
BIOBASE/Current Awareness in Biological Sciences BIOSIS Preview (Clarivate Analytics) Biological Abstracts CINAHL Clinical Nuclear Medicine CML Breast Cancer CML Colorectal Cancer CML Leukaemia and Lymphoma CML Lung Cancer Current Clinical Cancer Current Contents - Life Sciences (Clarivate Analytics) EMBASE (Elsevier) EMCare (Elsevier) Index Medicus (NLM) INSPEC Medical Documentation Service Medline (NLM) PESTDOC Pubmed (NLM) PubMed Central Selective Deposit Medicine & Health (NLM) Reference Update Research Alert Science Citation Index (Clarivate Analytics) Science Citation Index Expanded (Clarivate Analytics) Scopus (Elsevier)
Acta Oncologica Foundation and our publisher Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Acta Oncologica Foundation and our publisher Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Acta Oncologica Foundation and our publisher Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Acta Oncologica Foundation and our publisher Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110803/Subject-Sample-2021-Bioscience.jpg"})
![F1000Research. The Oncology Gateway. Accepting multiple article types. Submit now.]({"type":"image" , "src" : "/sda/112413/JournalAd-F1000-Oncology.jpg"})